Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei
Jyong Biotech (Nasdaq: MENS), a Taiwan-based biotechnology company focused on plant-derived drugs for urinary system diseases, announced its Chairwoman and CEO Fu Feng Kuo will speak at The 2025 Global Business Forum on September 19, 2025.
The event, held at the Taipei International Convention Center, is organized by the Taiwanese Chambers of Commerce of North America in partnership with U.S. venture capital and biotech industry representatives. The forum will focus on three key themes: innovative drug technology development, cross-border clinical collaboration, and strategic capital deployment.
- None.
- None.
New Taipei City, Taiwan, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that its chairwoman and chief executive officer, Fu Feng Kuo, has been invited to speak at The 2025 Global Business Forum (the “Forum”) on September 19, 2025, at the Taipei International Convention Center.
Chairwoman Kuo will join Taiwan biotech industry leaders to discuss the topic, “How can Taiwan align its biotech and medical industries with global trends?” The Forum, organized by the Taiwanese Chambers of Commerce of North America (TCCNA) in collaboration with U.S. venture capital and biotechnology industry representatives, will serve as a high‑level international business matchmaking platform.
The event intends to bring together influential U.S. biotech decision‑makers and Taiwan’s leading new drug development enterprises for direct dialogue. Discussions will focus on three core themes:
- Innovative drug technology development
- Cross‑border clinical collaboration
- Strategic capital deployment
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.
For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email: services@wealthfsllc.com
Phone: +1 628 283 9214
FAQ
When and where will Jyong Biotech (MENS) CEO speak at the 2025 Global Business Forum?
What will be the main topic of Jyong Biotech (MENS) CEO's discussion at the Forum?
What are the three main themes of the 2025 Global Business Forum where Jyong Biotech (MENS) will present?
What is Jyong Biotech's (MENS) main business focus?
